The Occurrence of Four Globin Abnormalities in One Individual: Hb SC Disease with Hb Chicago and Deletional Alpha Thalassemia.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3802-3802
Author(s):  
Heather Hughes ◽  
Ferdane Kutlar ◽  
Kathleen M. McKie ◽  
Leslie Holley ◽  
Dedrey Elam ◽  
...  

Abstract The occurrence of multiple globin abnormalities in one individual is not very rare, particularly in populations where hemoglobinopathies are common. In most cases, this is of genetic interest and may pose a diagnostic challenge due to the interaction of the products of mutant α and β globin genes and the presence of hybrid hemoglobins. Co-inheritance of α globin variants with sickle cell disease (Hb SS or SC) could have an effect on the disease phenotype particularly when the variant in question has altered functional properties (decreased or increased oxygen affinity) or stability. We report a patient with Hb SC disease with co-inheritance of the α chain variant, Hb Chicago (α136Leu→Met), and deletional α thalassemia (−α3.7) in trans to the Hb Chicago mutation. The patient is a 3-year old African-American male referred to the Pediatric Sickle Cell Clinic from the local Health Department. He is the product of an uneventful term pregnancy and a normal labor. He presented with seizures at age 3 weeks and underwent a neurologic evaluation which failed to reveal any abnormality. His subsequent course was uneventful without further seizures after 1 year of age and no hospitalizations. Physical exam was unremarkable with normal growth. A CBC showed Hb of 11.3 g/dl, Hct 35.2%, MCV 64.8 fl, MCH 20.8, MCHC 32.1, RDW 18.4%, retic count of 1.7% (absolute retic count of 92,480). Cation exchange HPLC revealed a Hb F of 6.8%, A2 3.3%, Hb S 33.1% and Hb C 30.0%. Both Hb S and Hb C peaks were followed by an additional peak of 13.2% (Hb SX) and 13.6% (Hb CX) respectively suggesting the presence of an α chain variant. The total quantity of Hb S was 46.3% (Hb S+Hb SX) and that of Hb C was 43.6% (Hb C+ Hb CX), whereas Hb X amounted to 26.8%. A reversed phase HPLC confirmed the presence of an α chain variant, which eluted earlier than normal α chains; αX constituted 37.5% of the total α chains. Sequencing of the β-globin gene confirmed the presence of Hb S (GAG→GTG) and Hb C (GAG→AAG) mutations in codon 6. A PCR for α globin deletions confirmed heterozygosity for the -α3.7 deletion. α globin sequencing revealed an apparent homozygosity for a CTG→ATG (Leu→Met) substitution of the codon 136 in α2 globin gene; this “apparent” homozygosity is due to the -α3.7 deletion in trans. Family studies showed that the patient’s mother had Hb C trait with heterozygous α-thalassemia; the father was not available. The paternal grandmother had normal α-globin gene numbers, with heterozygous Hb Chicago, which was quantitated at 20.7%. Thus, the patient’s genotype was ascertained as βS/βC;-α/αChicagoα. Hb Chicago has been reported in conjunction with Hb SS but not with Hb SC disease. The co-inheritance of the α-chain variant, Hb G-Philadelphia (α68Asn→Lys) and Hb SC disease, has been reported by Lawrence et al (Blood90:2819–25, 1997); this combination resulted in the acceleration of Hb C crystal formation and decreased Hb S polymerization with a resultant mild sickling disorder. α136 is a heme contact; the Leu→Met substitution in Hb Chicago does not alter the functional properties or the stability of the molecule and is not associated with any hematologic abnormalities in heterozygous carriers. This residue is not involved in intermolecular contacts of deoxy Hb S and hence is not expected to alter the kinetics of deoxy Hb S polymerization. The significance of this observation is the accurate diagnosis of the complex Hb phenotype and ascertainment of its lack of interaction with the sickling or crystallization process.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3849-3849
Author(s):  
Ferdane Kutlar ◽  
Mary Ann Knovich ◽  
Dedrey Elam ◽  
Daniel B. Jobe ◽  
David H. Buss ◽  
...  

Abstract The co-existence of Hemoglobin H (Hb H) disease and heterozygosity for β-chain structural variants is a rare occurrence. Hb H disease has been reported in conjunction with Hb E, Hb C, Hb S, and Hb Hamilton. The combination of Hb H disease with Hb C and Hb S reportedly results in a mild hemolytic anemia without detectable Hb H. We present a new case of atypical Hb H disease that was also heterozygous for the rare β-chain variant Hb Raleigh. The patient is a 27-year-old Cambodian female referred for the evaluation of microcytic anemia unresponsive to iron. She had a lifelong history of generalized fatigue, exertional dyspnea, and weakness in her legs. Physical exam was unremarkable except for pallor of mucuous membranes. There was no hepatosplenomegaly. She had a Hb of 9.7, HCT 30.8, MCV 56, MCH 17.6, MCHC 31.5, ferritin 92. Hb analysis on IEF revealed Hb A, Hb A2, and an abnormal band slightly more anodic to Hb A. No Hb H was observed. On cation exchange HPLC, she had 49.7% Hb A, 48.1% Hb X, and 2.2% Hb A2. Reverse phase HPLC revealed a βx chain eluting immediately before βA. Oxygen affinity was slightly reduced. PCR amplification and sequencing of the β-globin gene revealed heterozygosity for Hb Raleigh (Exon 1, codon 1, GTG→GCG, VAL→ALA). The patient was also found to be a compound heterozygote for -α3.7 and --SEA deletions. This case represents a novel interaction of a structural β-chain variant with Hb H disease. Hb Raleigh has previously been reported in Caucasians and in two Swedish families. It has decreased oxygen affinity. This is the first report of this variant in a Cambodian population. The absence of any detectable Hb H likely results from the inability of variant β-chains to form a viable tetramer with a resultant decrease in βA. The low oxygen affinity did not negatively impact on the degree of anemia. This case, like some others reported previously, shows that the accurate diagnosis of Hb H disease in association with structural β-chain variants can be established by molecular methods, and the detection of Hb H on electrophoretic and chromatographic analyses may not always be reliable.


Author(s):  
Akueté Yvon Segbena ◽  
Claude Prehu ◽  
Henri Wajcman ◽  
Josiane Bardakdjian-Michau ◽  
Kodjovi Messie ◽  
...  
Keyword(s):  
Hb S ◽  

Blood ◽  
1992 ◽  
Vol 79 (3) ◽  
pp. 787-792 ◽  
Author(s):  
J Elion ◽  
PE Berg ◽  
C Lapoumeroulie ◽  
G Trabuchet ◽  
M Mittelman ◽  
...  

The clinical diversity of sickle cell anemia is strongly related to the degree of intracellular hemoglobin S (Hb S) polymerization, which in turn is dependent on the intracellular concentration of Hb S. We have recently defined a region of DNA approximately 500 bp 5′ to the human beta-globin gene that acts as a silencer for the transcription of this gene and have shown that a polymorphism in this sequence is associated with a thalassemic phenotype of the beta-globin gene. In this work we have examined the correlation of DNA sequence polymorphisms in this silencer with binding of a previously identified putative repressor protein, BP1, and with the expression of Hb S in individuals heterozygous for the beta s allele. It was found that specific configurations of the motif, (AT)x(T)y, are homogeneous for the major haplotypes of the beta-globin gene cluster described on beta s chromosomes. Binding of BP1 was measured to DNA of three haplotypes: Indian, Benin, and Bantu. BP1 binds most tightly to DNA of the Indian haplotype, and these patients produce less beta s protein than Benin patients, whose DNA exhibits weaker affinity for BP1. Binding of BP1 is the weakest to DNA of the Bantu haplotype, which is associated with clinically more severe sickle cell symptoms. These data are consistent with the hypothesis that these polymorphisms may not be neutral and that the DNA sequence at this site may affect the expression of the beta s gene. Such an effect may be synergistic with other genetic variables, such as fetal hemoglobin levels, F-cell numbers, and the number of alpha-globin genes, in determining intracellular polymerization and, thus, the severity of the sickle cell syndromes.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4062-4062
Author(s):  
Martin K. Safo ◽  
J. Eric Russell

Abstract Important therapeutic approaches to sickle-cell disease (SCD) are based upon the observation that the abnormal properties of Hb S (Hb α2βS2) can be mitigated by exchanging the pathological βS-globin subunit for a related β-like subunit. We previously demonstrated that exchange of the non-pathological α-globin subunit for a ζ-globin subunit (a developmentally silenced globin that can be derepressed both by natural and experimental conditions) inhibits deoxyHb S polymer assembly in vitro and reverses hematological, biochemical, and physiological characteristics of SCD in mouse models in vivo. While its therapeutic potential is clear, the underlying structural basis for the profound antipolymer activity of ζ-substituted Hb S (Hb ζ2βS2) is less certain. X-ray crystallographic studies conducted at 1.95Å resolution revealed that liganded (CO-) Hb ζ2βS2 is trapped in a tense (T-state) quaternary structure, rather than in a relaxed (R-state) structure that is characteristic of nearly all liganded hemoglobins. Specifically, CO-Hb ζ2βS2 exhibited several intact T-state intersubunit salt-bridge/hydrogen-bond interactions, a preserved T-state ζ1-β2 (ζ2-β1) interface, and a characteristically enlarged T-state central water cavity and β-cleft. This structure wrongly predicts that liganded Hb ζ2βS2 will be included, rather than excluded, from the deoxyHb S polymer; and suggests that changes in the positions or the biochemical identities of individual amino acids, rather than the overall quaternary structure of liganded Hb ζ2βS2, are the chief determinants of its antipolymer activity. To define key differences in the structures of T-state deoxyHb α2βS2 and CO-Hb ζ2βS2, we superposed their corresponding globin subunits and calculated the specific displacement of individual amino-acid residues as root mean square deviation (rmsd) values. Among βS-chain residues, α→ζ exchange effects a significant 1.9Å shift in the position of the pathological βSVal6, and correspondingly large displacements of βThr4 (2.2Å) and βAsn19 (1.4Å); each repositioning predicts weakening of an intermolecular interaction that would otherwise stabilize the deoxyHb S polymer. Similar superposition analyses of the α and ζ chains reveal a significant displacement of αPro114 (1.3Å), a well-described determinant of deoxyHb S polymerization that is conserved between the two α-like subunits. Three additional α-chain residues that stabilize the deoxyHb S polymer undergo nonconservative replacement in the ζ-globin chain, but are not materially repositioned: αHis20→ζGln (basic→neutral polar), αAsn68→ζAsp (neutral polar→acidic), and αAsn78→ζGly (neutral polar→neutral). While all three replacements are predicted to weaken or ablate intermolecular contacts, the αHis20→ζGln substitution is particularly noteworthy as it reproduces the specific mutation that defines the naturally occurring anti-sickling variant αLe Lamentin. Finally, we considered the possibility that ζ-substituted Hb S is fully excluded from the deoxyHb S polymer--and therefore reduces the rate of its assembly--by comparing the crystal packing of the two hemoglobins. While deoxyHb α2βS2 packs in a familiar two-strand structure, CO-Hb ζ2βS2 assembles into a unique trimeric arrangement comprising three lateral heterotetramers, each of which interacts with an axial heterotetramer that is constituent to a separate trimer assembly. This remarkable structure is sustained by intermolecular interactions that are distinct from those observed for deoxyHb S. Moreover, the calculated buried solvent-accessible surface area for CO-Hb ζ2βS2 (4806Å2) is nearly two-fold higher than for deoxyHb α2βS2 (2510Å2), suggesting that Hb ζ2βS2 exists in solution as a stable trimer of heterotetramers, and validating the hypothesis that Hbs α2βS2 and ζ2βS2 do not co-assemble in solution. In sum, our crystal analyses indicate that the antipolymer activities of liganded Hb ζ2βS2 arise through movements in the positions of βS-chain residues, and through changes in the identities of α-chain residues. Our studies also demonstrate a novel packing structure for T-state liganded Hb ζ2βS2 that is consistent with its exclusion from the deoxyHb S polymer. These data account for the significant antipolymer activity of ζ-substituted Hb S, and recommend the utility of therapeutic approaches to SCD that are based upon α-globin subunit exchange. Disclosures Safo: Baxter and AesRx companies have licensed our patented antisickling compounds. Consulted with AesRx LLC during phase I clinical studies of the antisickling compound, 5HMF for the treatment of sickle cell disease: #7160910; #7119208 Patents & Royalties, Consultancy, Research Funding.


Blood ◽  
1964 ◽  
Vol 23 (2) ◽  
pp. 206-215 ◽  
Author(s):  
REGINALD P. PUGH ◽  
THOMAS V. MONICAL ◽  
VIRGINIA MINNICH

Abstract Hemoglobin studies have been presented on a patient with clinically typical sickle cell anemia who was found to possess two major adult hemoglobins, Hb S and hybrid Hb GPhil./S. Four hemoglobins were demonstrated in his mother, Hb A, GPhil., S and GPhil./S, in somewhat unexpected and as yet unexplained proportions. To our knowledge the propositus represents the first description of an individual with a homozygous β chain defect accompanied by a heterozygous α chain abnormality.


2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S110-S111
Author(s):  
D Dolezal ◽  
C Tormey ◽  
H Rinder ◽  
A J Siddon

Abstract Casestudy Hemoglobin Korle-Bu (Hb-KB) is an uncommon Hb variant that can be mistaken for Hb-S on electrophoretic screening. While Hb-KB alone has no clinical manifestations, there are only limited case studies describing KB in combination with other Hb variants. Here we report a rare case of Hb-C/KB misdiagnosed and managed as Hb-S/C disease for over 20 years. Results A 21-year-old African American woman with presumed Hb-S/C disease presented with generalized abdominal pain, nausea, and vomiting. In 1999, Hb electrophoresis showed 59% of abnormal hemoglobin presumed to be HbS and 41% HbC+A2; agar/acetate gel analysis was not employed and the hemoglobinopathy remained incompletely characterized. She had a history of back, chest, abdomen, and extremity pains requiring multiple hospital admissions, with treatments including dilaudid, oxycontin, oxycodone, and hydroxyurea. Her vital signs were normal and her examination was only significant for abdominal tenderness. Imaging studies did not show any evidence vascular occlusion, avascular necrosis, or end-organ dysfunction. RBC indices were remarkable for mild borderline anemia, microcytosis, decreased MCH/elevated MCHC, and borderline elevated RDW. Peripheral smear showed microcytic red cells with anisocytosis, scattered target cells, and a notable absence of sickled cells and Hb-C-crystals. The diagnosis of Hb-S/C disease was then revisited. HPLC showed abnormal hemoglobins in the Hb-D window at 55.1% and in the Hb-C window at 40.6%, with 3.5% Hb-A2 and no normal Hb-A. Gel electrophoresis with cellulose acetate followed by citrate agar suggested Hb-C in combination with either D, G, or Korle-Bu. Definitive diagnosis was obtained by beta globin gene sequencing that demonstrated one copy Hb-C (19G>A, Glu7Lys) and one copy Hb- Korle-Bu (220G>A, Asp74Asn). Given the absence of Hb-S/C disease, her gastrointestinal distress and pain episodes were re-evaluated. Conclusion Hb-S and Hb-Korle-Bu migrate similarly in cellulose acetate electrophoresis but can be distinguished on citrate agar. Challenging beta chain variants can now be readily differentiated by complete gene sequencing. This case study emphasizes the importance of distinguishing Hb-KB from clinically-significant Hb-S.


2020 ◽  
Vol 7 (5) ◽  
pp. 1174
Author(s):  
Manoj Kumar D. ◽  
Komalatha Choppari ◽  
Suresh R. J. Thomas

Sickle cell disease (SCD) is a term used for a group of genetic disorders characterized by production of Hb “S”. Sickle cell hemoglobin opathy occurs due to mutation of beta-globin gene situated on short arm of chromosome 11, where adenine is replaced by thymine in base of DNA coding for the amino acid in the sixth position in beta-globin chain. This leads to an amino acid change in beta chain of Hb molecule, from glutamic acid to valine. The result is profound change in the molecular stability and solubility of Hb “S”. Authors are reporting a 8-year-old girl who is a known case of sickle cell disease presented with complaints of intermittent pain abdomen and vomiting since 30 days. Investigations revealed elevated pancreatic enzymes with radiological evidence of pancreatitis. Packed red blood cell transfusion and appropriate supportive therapy given and child recovered well.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4206-4206
Author(s):  
Dr Yvonne Daniel ◽  
Stephen Obaro ◽  
John Dada ◽  
Juliana Olufunke Lawson ◽  
Baba PD Inusa

Abstract Abstract 4206 An integral part of an EU-UNDP funded pilot sickle cell screening project, was the installation, in Abuja (Federal Capital Territory) Nigeria, June 2010, of a High Performance Liquid Chromatography (HPLC) instrument. Prior to the installation, haemoglobinopathy screening was carried out using only unstained paper electrophoresis. Minor bands were difficult to visualise and the proportions of haemoglobins were not measured. Full blood count (FBC) data was also not routinely available. Therefore awareness of both alpha and beta thalassaemia was low as was the implications of coinheritance of beta thalassaemia with haemoglobin (Hb) S. Stratified community surveys were carried out with samples collected as Guthrie card blood spots; children aged less than 6 months, and whole blood; children aged between 6 months and 5 years. Blood spot samples were analysed using newborn sickle cell screening reagents and whole blood samples using beta thalassaemia short reagents, the later allowing accurate Hb A2 and Hb F measurement. Samples were processed on a Biorad™ Classic (instrument and reagents, Biorad, Hercules, CA.). Reporting algorithms were defined for both reagent sets. Using the beta thalassaemia reagents, Hb S/beta thalassaemia was considered when Hb S was predominant, Hb A absent or significantly reduced and the Hb A2>5. Over 10,000 samples were analysed, 410 had sickle cell disease, of which 370 were transported to London for further analysis, 70 of these had an Hb A2>5%, mean and range 5.9(5.1 – 9.1)%. To validate the algorithm 31 samples (Hb A2 3.5 – 7.4%), were selected for beta gene sequencing (Mai et al, 2004) and/or PCR analysis for the 7 common alpha gene deletions (3.7kb, 4.2kb, SEA, MED, THAI, FILL, 20.5kb and triplicated alpha gene locus, anti 3.7kb), (Chong et al, 2000, Wang et al, 2003). Five samples had an Hb A2of 3.5 – 4.9%, 2 with Hb A present (23 and 25%), all were Hb SS, 4 negative for alpha thalassaemia deletions and 1 heterozygous for the alpha 3.7kb deletion. Sixteen samples had an Hb A2 of 5.0 – 5.9%, all were Hb SS, 5 negative for alpha thalassaemia deletions and 11 heterozygous for the alpha 3.7kb deletion. Seven samples had an Hb A2 of 6.0 – 6.9%, 6 were Hb SS, 1 negative for alpha thalassaemia deletions, 1 heterozygous and 4 homozygous for the alpha 3.7kb deletion. One, Hb A2 6.9%, was a compound heterozygote for Hb S/ beta zero codon 106/107(+G) mutation. Three samples had an Hb A2 of 7.0 – 7.4%, review of chromatograms indicated that all showed poor chromatography due to lack of separation between Hb A2 and Hb S or shoulders to the left of the Hb A2 peak. All were Hb SS and heterozygous for the alpha 3.7kb deletion, with 1 also positive for the triplicated alpha globin gene, anti 3.7kb. Four other samples with Hb A2 >7% also showed poor chromatography, but were insufficient for molecular testing. The results indicate that Hb A2values >5% were mainly due to co-existing alpha thalassaemia with 76% of those tested, positive for the 3.7kb deletion. Poor chromatography was also a contributor particularly at the higher Hb A2 levels. During the initial stages of the project air conditioning failure caused major temperature fluctuations on overnight runs, this problem was resolved, improving chromatography. One case of S/beta zero thalassaemia was detected confirming the presence in this population. The results suggest that the Hb A2 may be considered as a discriminator for S/beta thalassaemia screening in this setting, increasing the algorithm Hb A2 level to >6.0% may improve specificity and reduce the number of false positives, this warrants further investigation. Future aims of the project for children over 6 months of age, include initiating routine FBC analysis and testing parental samples as a cost effective means of confirming suspected cases. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1308-1308 ◽  
Author(s):  
Louis MINE ◽  
Thao Nguyen-Khoa ◽  
Birch Allaf ◽  
Jean-Antoine Ribeil ◽  
Christelle Remus ◽  
...  

Abstract Context: The principle of Sickle Scan (Biomedomics, Inc.) is a rapid, point-of-care qualitative lateral flow immuno-assay kit for the identification of sickle cell conditions of Hb A, S and C. Sickle Scan was specifically developed to allow for the identification of sickle cell trait Hb AS, heterozygotes AC, and Hb SS, Hb SC and Sβ° patients. Other sickle cell conditions as SD, SE, SO-Arab, S Lepore,… cannot be identified using Sickle Scan system. The test must be done using venous blood or capillary blood (fresh or dried blood spots). Patients and methods: Two hundred and fifty patient samples (143 adults and 107 newborns) were analyzed. All tests were performed according the manufacturer's recommendations in one laboratory by 2 observers. The reference tests used for comparison were HPLC (NBS Variant - Bio-Rad) and capillary electrophoresis (Capillarys 3 - Sebia). Results: Comments: In adult patients, the 2 observers concordantly detected the presence of Hb A, Hb S and Hb C. There were 4 differences of interpretation between them (no Hb A in a AS patient and no Hb A in 3 SS transfused patients). The percentage of Hb A in these 3 last patients was respectively 13.6%, 17.7% and 18%. There was no false positivity neither in the patient heterozygous AE nor in the patient SD. No false negativity occurred for Hb S and C. In newborns, the accuracy of the test was excellent for the identification of the phenotypes FA, FAS, FAC, FS (SS / Sβ°). The lowest detected values of Hb S and Hb C in FAS and FAC newborns were respectively 2.4 and 3.4 %. We observed an inconstant cross-reactivity of the antibody anti Hb S with the hemoglobins E and D, in respectively 3/25 FAE phenotype and 6/26 in the FAD phenotype. There was no cross reaction with hemoglobin Bart's and O-Arab. In FAS newborns the mean and extreme values of the percentage of Hb A were m=8.2 (2.6-15.5) and no difficulties occurred for the identification of these low percentages of Hb A. This observation is different from those made in adult patients for which one observer did not find Hb A in transfused patients with highest values of Hb A comprised between 13.6 and 18. Conclusions: In this series of adult and newborn patients, the Sickle Scan appeared as an accurate method for the identification of AS, AC, SS/Sβ° and SC phenotypes. False positive tests were observed in some patients with hemoglobin E or D but no false negative results were found as regards the identification of Hb S and Hb C. Table Table. Disclosures Ribeil: Bluebirdbio: Consultancy; Addmedica: Research Funding.


Sign in / Sign up

Export Citation Format

Share Document